prednisone has been researched along with Debility in 10 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The first application uses a classic textbook example on prednisone treatment and liver functioning among liver cirrhosis patients." | 3.96 | Estimating the number and length of episodes in disability using a Markov chain approach. ( Dudel, C; Myrskylä, M, 2020) |
| "Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment." | 2.94 | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. ( Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E, 2020) |
| "Older age and higher frailty score were significantly associated with increased risk for serious infection." | 1.72 | Giant cell arteritis treatment patterns and rates of serious infections. ( Jin, Y; Kim, SC; Lee, H; Pethoe-Schramm, A; Tedeschi, SK; Vine, S; Yau, V, 2022) |
| "Frailty is a significant risk factor for poor outcomes among older patients with diffuse large B-cell lymphoma (DLBCL)." | 1.72 | Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma. ( Chan, H; Disperati, P; Elinder-Camburn, A; Leitch, S; Merriman, E; Zhang, J, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 8 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tedeschi, SK | 1 |
| Jin, Y | 1 |
| Vine, S | 1 |
| Lee, H | 1 |
| Pethoe-Schramm, A | 1 |
| Yau, V | 1 |
| Kim, SC | 1 |
| Zhang, J | 1 |
| Disperati, P | 1 |
| Elinder-Camburn, A | 1 |
| Merriman, E | 1 |
| Leitch, S | 1 |
| Chan, H | 1 |
| Ugarte-Gil, MF | 1 |
| Dubey, J | 1 |
| McGwin, G | 1 |
| Reveille, JD | 1 |
| Vilá, LM | 1 |
| Alarcón, GS | 1 |
| Yagi, Y | 1 |
| Kanemasa, Y | 1 |
| Sasaki, Y | 1 |
| Goto, S | 1 |
| Yamamura, Y | 1 |
| Ishimine, K | 1 |
| Hayashi, Y | 1 |
| Mino, M | 1 |
| Ohigashi, A | 1 |
| Morita, Y | 1 |
| Tamura, T | 1 |
| Nakamura, S | 1 |
| Okuya, T | 1 |
| Shimoyama, T | 1 |
| Facon, T | 1 |
| Dimopoulos, MA | 1 |
| Meuleman, N | 1 |
| Belch, A | 1 |
| Mohty, M | 1 |
| Chen, WM | 1 |
| Kim, K | 2 |
| Zamagni, E | 1 |
| Rodriguez-Otero, P | 1 |
| Renwick, W | 1 |
| Rose, C | 1 |
| Tempescul, A | 1 |
| Boyle, E | 1 |
| Manier, S | 1 |
| Attal, M | 1 |
| Moreau, P | 1 |
| Macro, M | 1 |
| Leleu, X | 1 |
| Lorraine Chretien, M | 1 |
| Ludwig, H | 1 |
| Guo, S | 1 |
| Sturniolo, M | 1 |
| Tinel, A | 1 |
| Silvia Monzini, M | 1 |
| Costa, B | 1 |
| Houck, V | 1 |
| Hulin, C | 1 |
| Yves Mary, J | 1 |
| Lee, HS | 1 |
| Kim, SJ | 1 |
| Lee, JJ | 1 |
| Kim, I | 1 |
| Kim, JS | 1 |
| Eom, HS | 1 |
| Yoon, DH | 1 |
| Suh, C | 1 |
| Shin, HJ | 1 |
| Mun, YC | 1 |
| Kim, MK | 1 |
| Lim, SN | 1 |
| Choi, CW | 1 |
| Kang, HJ | 1 |
| Yoon, SS | 1 |
| Min, CK | 1 |
| Dudel, C | 1 |
| Myrskylä, M | 1 |
| Cordoba, R | 1 |
| Luminari, S | 1 |
| Eyre, TA | 1 |
| Beygi, S | 1 |
| Sadashiv, S | 1 |
| Reilly, JB | 1 |
| Khan, C | 1 |
| Lister, J | 1 |
| Chaganti, S | 1 |
| Illidge, T | 1 |
| Barrington, S | 1 |
| Mckay, P | 1 |
| Linton, K | 1 |
| Cwynarski, K | 1 |
| McMillan, A | 1 |
| Davies, A | 1 |
| Stern, S | 1 |
| Peggs, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.[NCT05527340] | Phase 2 | 140 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)[NCT04891809] | Phase 2 | 198 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | ||
| A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000] | Phase 3 | 226 participants (Anticipated) | Interventional | 2017-07-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for prednisone and Debility
| Article | Year |
|---|---|
The use of frailty assessments in treating older adults with aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2021 |
Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2018 |
2 trials available for prednisone and Debility
6 other studies available for prednisone and Debility
| Article | Year |
|---|---|
Giant cell arteritis treatment patterns and rates of serious infections.
Topics: Aged; Anti-Bacterial Agents; Female; Frailty; Giant Cell Arteritis; Humans; Immunosuppressive Agents | 2022 |
Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Electronics; Fr | 2022 |
Association of Systemic Lupus International Collaborating Clinics Frailty Index With Damage in Systemic Lupus Erythematosus Patients: Results From a Multiethnic, Multicenter US Cohort of Patients With Lupus.
Topics: Adult; Ethnicity; Female; Frailty; Humans; Lupus Erythematosus, Systemic; Male; Middle Aged; Prednis | 2023 |
Utility of the frailty score for predicting prognosis and individualizing treatment intensity in elderly patients with diffuse large B cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Frailty; Humans | 2023 |
Estimating the number and length of episodes in disability using a Markov chain approach.
Topics: Activities of Daily Living; Algorithms; Disabled Persons; Frailty; Humans; Life Expectancy; Liver Ci | 2020 |
Guidelines for the management of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |